TIDMYGEN
RNS Number : 1264N
Yourgene Health PLC
28 September 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
AGM Statement
Investor presentation
Manchester , UK - 28 September 2021: Yourgene (AIM: YGEN), a
leading international molecular diagnostic group, will be holding
its Annual General Meeting (AGM) at 4:00pm today. In-person
registration for this meeting is now closed due to COVID-19
protocols in place but investors can still attend via the Investor
Meet Company website as described at the end of this notice.
At the meeting Adam Reynolds, Non-executive Chairman, will make
the following statement:
"I am delighted to welcome longstanding and recent shareholders
to our Annual General Meeting. Despite the eventful backdrop since
our last AGM and as described in our recent results announcement,
the business has enjoyed improved momentum and evolved its service
offering significantly within both of our Genomic Services and
Genomic Technologies business segments . The Company now finds
itself at a very exciting juncture with record business activity
levels in Genomic Services, including our UK COVID-19 testing
service, and a growing pipeline of opportunities in Genomic
Technologies, especially in the North American market where travel
is now thankfully reopening. The combination of these growth
drivers is expected to deliver first half-year revenues to 30
September 2021 of at least GBP15m. This compares favourably to the
first half in the prior year of GBP8.2m and full year 2020-21
revenues of GBP18.3m.
"The reopening of UK-US travel is a very welcome development. It
allows Yourgene's UK-based capabilities to be more fully deployed
to assist our growing North American team, as they develop their
partnerships with leading diagnostic majors and build on the
recently announced contract wins in March and June 2021. The
acquisition of Coastal Genomics in August 2020 has proven a
catalyst for these partnerships and we look forward to working with
our Canadian colleagues on a face-to-face basis for the first time
in the coming months. The Ranger(R) sample preparation technology
acquired with Coastal continues to be an important differentiator
in helping to support our North American new business
development.
"No-one can be sure of the trajectory for PCR COVID testing, as
witnessed by recent news on changing UK travel protocols, but
currently PCR testing remains the gold standard and Yourgene's
participation in domestic testing through the National Microbiology
Framework and private channels give us an outstanding position to
participate fully in this important national endeavour. We are now
operating at our previously announced capacity of 100,000 tests per
month and have now doubled that capacity in anticipation of
continued growth in sample numbers.
"Our long-term strategy remains to build an international
molecular diagnostics business of scale, and we have plans to
redeploy COVID-generated funds into further enhancing our core
Genomic Service and Genomic Technology business streams. We are
maintaining a conservative approach to forecast guidance regarding
COVID testing and other revenue, but will provide further updates
as appropriate, as the second half progresses."
Following the formal business of the AGM, the Company's CEO, Lyn
Rees, will provide shareholders with a short presentation via the
Investor Meet Company platform and there will be an opportunity for
investors to submit questions. Investors can sign up to Investor
Meet Company for free and register for the Yourgene
Health meeting via: https://www.investormeetcompany.com/yourgene-health-plc/register-investor
The presentation recording and responses to investor questions
will be made available on the Investor Meet
Company platform at the earliest opportunity.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation. The Directors of the Company
take responsibility for this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health plc
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genomic services and
technologies. The group works in partnership with global leaders in
DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and infectious diseases.
The Group's flagship in vitro diagnostic products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other
genetic disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests and DPYD genotyping.
Yourgene has a range of innovative DNA sample preparation
platforms, powered by Ranger(R) Technology, the Yourgene
LightBench(R) and Yourgene QS250, ideal for cell-free DNA
applications in NIPT and oncology including liquid biopsy.
Yourgene Genomic Services is a global laboratory service network
equipped to be a full life-cycle partner for clinical, research and
pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop,
manufacture, obtain regulatory approval and commercialise new
products and services. In addition, Yourgene Genomic Services
offers an NIPT and high throughput COVID testing service.
Yourgene Health is headquartered in Manchester, UK with
facilities in Taipei, Singapore, the US and Canada, and is listed
on the London Stock Exchange's AIM market under the ticker "YGEN".
Follow us on LinkedIn and Twitter .
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMDKOBBABKDPCB
(END) Dow Jones Newswires
September 28, 2021 01:59 ET (05:59 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024
